WXXWY:OTCMKTS
Wuxi Biologics Cayman ADR
၁၂.၅၆ US$
arrow_upward
+၀.၄၈%(+၀.၀၆၀) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for WXXWY...
Open
၁၂.၂၉ US$
High
၁၂.၅၆ US$
Low
၁၂.၂၀ US$
Mkt. cap
ဋေ ၁.၉၈ သ
Avg. vol.
၆.၁၉ သောင်း
Volume
၁.၁၁ သိန်း
52-wk high
၁၄.၈၀ US$
52-wk low
၇.၃၀ US$
Beta
၀.၀၁
Shares outstanding
၂၀၅.၈၄ ဋေ
No. of employees
၁ သောင်း
Open
၁၂.၂၉ US$
High
၁၂.၅၆ US$
Low
၁၂.၂၀ US$
Mkt. cap
ဋေ ၁.၉၈ သ
Avg. vol.
၆.၁၉ သောင်း
Volume
၁.၁၁ သိန်း
52-wk high
၁၄.၈၀ US$
52-wk low
၇.၃၀ US$
Beta
၀.၀၁
Shares outstanding
၂၀၅.၈၄ ဋေ
No. of employees
၁ သောင်း
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
S&P 500, Nasdaq futures rise as AI stocks rebound ahead of key earnings
GlobeNewswire
·
ပြီးခဲ့သည့် ၅၆ မိနစ်
Owlting Group (NASDAQ: OWLS) Issues CEO Letter to Shareholders Marking One Year on Nasdaq
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
Leadership Change Could Reset The Case For Erasca (ERAS) Stock
The Motley Fool
·
ပြီးခဲ့သည့် ၃၂ မိနစ်
The S&P 500's Worst Day Was 39 Years Ago Today. Should You Buy When Stocks Crash?
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics Cayman ADR